InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.75
(
-0.19%
)
Bitcoin
57,111.00
(
-5.06%
)
Post# of 252478
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

lgonber

Send PM Follow Ignore
Followers 12
Posts 648
Boards Moderated 0
Alias Born 12/20/2014

lgonber

Re: DewDiligence post# 198194

Friday, 12/11/2015 4:13:02 PM

Friday, December 11, 2015 4:13:02 PM

Post# of 252478
But Acerta's new drug's label is limited in scope to Xalkori intolerant or nonresponding patients so even if they may see potential in other indications, I think that price is too high
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up